https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18999 Wed 27 Jul 2022 13:53:32 AEST ]]> Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14178 Wed 11 Apr 2018 11:03:59 AEST ]]> Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20549 Wed 11 Apr 2018 09:50:48 AEST ]]> HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34088 Wed 06 Feb 2019 16:16:15 AEDT ]]> Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24206 Tue 20 Aug 2024 12:15:13 AEST ]]> Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23224 Thu 04 Nov 2021 10:40:21 AEDT ]]> Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11140 Sat 24 Mar 2018 08:10:29 AEDT ]]> Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19000 Sat 24 Mar 2018 08:05:34 AEDT ]]> Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17517 Sat 24 Mar 2018 08:03:50 AEDT ]]> Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17782 Sat 24 Mar 2018 07:57:23 AEDT ]]> Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4862 30 kg/m²) reported more joint symptoms than women with a BMI of 25-30 kg/m² or those with a BMI <25 kg/m² (504 of 1354 women [37·2%] vs 502 of 1926 women [31·3%; OR 1·01 (0·88-1·16)] vs 592 of 1908 women [31·0%; OR 1·32 (1·14-1·53)]) and women on anastrozole reported more joint symptoms compared with those on tamoxifen (949 of 2698 women [35·2%] vs 829 of 2735 women [30·3%]; OR 1·25 [1·11-1·40]). All significant risk factors from the univariate analysis were included in a multivariate analysis and remained significant with little change. Interpretation: In this trial, the major risk factors for developing joint symptoms were previous HRT, hormone-receptor positivity, previous chemotherapy, obesity, and treatment with anastrozole. Discussion of identified risk factors is appropriate when counselling women before initiation of adjuvant hormonal treatment. Funding: This study was funded by Cancer Research UK and AstraZeneca (Macclesfield, UK).]]> Sat 24 Mar 2018 07:18:52 AEDT ]]> Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22830 interaction = 0.004). Estrogen receptor transcript levels showed inverse prediction across the time windows: HR, 0.88 (0.73–1.07) and 1.19 (0.99–1.43), respectively (Pinteraction = 0.03). Similar time-, module-, and estrogen-dependent relationships were seen for distant recurrence. Conclusions: Patients with tumors with high estrogen receptor transcript levels benefit most from 5 years' endocrine therapy but show increased recurrence rates after 5 years and may benefit from extended therapy. Improved prognostic profiles may be created by considering period of treatment and follow-up time.]]> Sat 24 Mar 2018 07:16:07 AEDT ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32264 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Mon 23 Sep 2019 11:46:30 AEST ]]> Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49499 Fri 19 May 2023 12:01:55 AEST ]]> Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19871 Fri 16 Aug 2024 15:10:59 AEST ]]>